The Role of Notch3 in Cancer

Aburjania, Zviadi; Jang, Samuel; Whitt, Jason; Jaskula‐Stzul, Renata; Chen, Herbert; Rose, J. Bart

doi:10.1634/theoncologist.2017-0677

Cited by 64 publications

(48 citation statements)

References 145 publications

(196 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17] Notch signaling in cancer can be oncogenic or tumorsuppressive. [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] The roles of DLLs as an important family of Notch ligands, have not been systematically elucidated. In this review, we provide a comprehensive overview of the role of DLLs in cancer and propose novel safe and effective DLL-targeted treatment strategies.…”

Section: Introductionmentioning

confidence: 99%

The Role of DLLs in Cancer: A Novel Therapeutic Target

Xiu

Liu

Kuang

2020

OTT

View full text Add to dashboard Cite

Delta-like ligands (DLLs) control Notch signaling. DLL1, DLL3 and DLL4 are frequently deregulated in cancer and influence tumor growth, the tumor vasculature and tumor immunity, which play different roles in cancer progression. DLLs have attracted intense research interest as anti-cancer therapeutics. In this review, we discuss the role of DLLs in cancer and summarize the emerging DLL-relevant targeting methods to aid future studies.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of DLLs in Cancer: A Novel Therapeutic Target

Xiu

Liu

Kuang

2020

OTT

View full text Add to dashboard Cite

show abstract

“…MATN3 low expression phenotype was associated with P53 signaling which has been identi ed as one of the key signaling pathways that inhibit gastric cancer. Notch receptor plays different roles in the genesis and development of tumor [17].…”

Section: Discussionmentioning

confidence: 99%

Overexpression of MATN3 predicts poor prognosis of gastric adenocarcinoma: based on TCGA database

Zheng¹,

Zhao²,

Zheng³

2020

Preprint

View full text Add to dashboard Cite

Background Matrilin-3 (MATN3) was previously reported to in the cartilage extracellular matrix and had a role in the development and homeostasis of cartilage and bone. We evaluated the role of MATN3 in gastric adenocarcinoma (GAC) using publicly available data from The Cancer Genome Atlas (TCGA). Methods The relationship between clinicapathologic features and MATN3 were analyzed with the Wilcoxon signed-rank test and logistic regression. Clinicopathologic variables associated with overall survival (OS) in TCGA patients using Cox regression and the Kaplan-Meier method. Gene Set Enrichment Analysis (GSEA) was performed using TCGA cohort. Results MATN3 overexpressed in GAC than that in normal tissues (p﹤0.05), and MATN3 overexpression was significantly associated with TNM stage (p= 0.012), and T stage (p﹤0.01). Kaplan-Meier survival analysis showed that GAC with MATN3 - high had a worse prognosis than that with MATN3- low (p﹤0.01). The univariate analysis revealed that MATN3- high correlated significantly with a poor OS (HR: 1.86; 95% confidence interval [CI]: 0.82- 2.01; p = 0.014). The multivariate analysis revealed that MATN3 remained independently associated with OS, with a HR of 2.68 (CI: 0.74- 2.13; p﹤0.01). GSEA showed that NOTCH, WNT, and MTOR signaling pathway were differentially enriched in MANT3 high expression phenotype. Conclusion Overexpression of MATN3 may be a potential prognostic biomarker of poor survival in gastric cancer, Moreover, NOTCH, WNT, and MTOR signaling pathway may be the key pathway regulated by MATN3 in GAC.

show abstract

“…Notch signaling activation occurs via an interaction between four Notch receptors (Notch 1–4) and five canonical ligands (Jag1, Jag2, Dll1, Dll3, and Dll4) [ 184 , 185 ]. It has been shown that Notch 1 and 2 share a similar basic structure and are ubiquitously expressed in a wide variety of tissues and cells types at varying levels [ 186 , 187 ]. In contrast, the expressions of Notch 3 and 4 are restricted to a more limited range of tissues and cell types, such as smooth muscle cells and vascular endothelial cells [ 188 , 189 ].…”

Section: Signaling Pathway-based Therapiesmentioning

confidence: 99%

Targeting Liver Cancer Stem Cells: An Alternative Therapeutic Approach for Liver Cancer

Lee

Hong

2020

Cancers

View full text Add to dashboard Cite

The first report of cancer stem cell (CSC) from Bruce et al. has demonstrated the relatively rare population of stem-like cells in acute myeloid leukemia (AML). The discovery of leukemic CSCs prompted further identification of CSCs in multiple types of solid tumor. Recently, extensive research has attempted to identity CSCs in multiple types of solid tumors in the brain, colon, head and neck, liver, and lung. Based on these studies, we hypothesize that the initiation and progression of most malignant tumors rely largely on the CSC population. Recent studies indicated that stem cell-related markers or signaling pathways, such as aldehyde dehydrogenase (ALDH), CD133, epithelial cell adhesion molecule (EpCAM), Wnt/β-catenin signaling, and Notch signaling, contribute to the initiation and progression of various liver cancer types. Importantly, CSCs are markedly resistant to conventional therapeutic approaches and current targeted therapeutics. Therefore, it is believed that selectively targeting specific markers and/or signaling pathways of hepatic CSCs is an effective therapeutic strategy for treating chemotherapy-resistant liver cancer. Here, we provide an overview of the current knowledge on the hepatic CSC hypothesis and discuss the specific surface markers and critical signaling pathways involved in the development and maintenance of hepatic CSC subpopulations.

show abstract

The Role of Notch3 in Cancer

Cited by 64 publications

References 145 publications

<p>The Role of DLLs in Cancer: A Novel Therapeutic Target</p>

<p>The Role of DLLs in Cancer: A Novel Therapeutic Target</p>

Overexpression of MATN3 predicts poor prognosis of gastric adenocarcinoma: based on TCGA database

Targeting Liver Cancer Stem Cells: An Alternative Therapeutic Approach for Liver Cancer

Contact Info

Product

Resources

About